HIV Infections
Conditions
Brief summary
This is a study of HIV vaccines. A vaccine is a medical product given to prevent certain diseases. The vaccine may educate the body to form a defensive response to try to prevent the disease from the beginning, or preventing it from taking hold of the body. This defensive response is called the immune response. The experimental vaccines in this study are Env-C Plasmid DNA and HIV Env gp145 C690 protein, given with different adjuvants. An adjuvant is a substance added to vaccines that can help make the vaccine more effective by improving the immune response, or by causing the immune response to last longer than it would without the adjuvant. The adjuvants are mixed with the vaccines and injected into muscle or placed on top of the skin. The HIV vaccines contain a piece of genetic material or a protein copied drom the HIV virus cover (Env), but they do not contain the virus itself. The vaccines cannot cause HIV infection or Acquired Immune Deficiency Syndrome (AIDS). The purpose of this study is to find out if the study vaccines with adjuvants cause side effects and are tolerable, whether humans respond (develop immune responses) to the vaccines, and how ling the effects of the study vaccines last. The study will also compare the effects of the study vaccines with adjuvants and adjuvant patch to those of placebo injections and placebo patch. The placebo will consist of saline (sterile saltwater) and will look like study vaccines, be given in the same way, but will have no active vaccine or adjuvant in it. A total of 126 participants will take part in the study and each will have up to 26 clinic visits and will be followed-up for a total of 108 weeks.
Detailed description
Antibodies are the most commonly recognized correlate of vaccine protection from infection; however the possible protective HIV antibody levels, which were induced by the modestly protective RV144 vaccine regimen with alum, rapidly decayed. Potentially, a novel, highly selective adjuvant combined with the correctly sequenced HIV antigen could slow antibody decay, increase antibody magnitude and induce antibodies of appropriate functional response. RV460 is an exploratory study that will assess the safety, tolerability, and immunogenicity of a vaccine regimen consisting of priming with an Env-C Plasmid DNA vaccine (with or without novel adjuvants) when given with or without adjuvanted HIV Env gp145 C.6980 protein vaccine and boosting with adjuvanted gp145 C.6980 protein with or without the gp120 DNA vaccine. The study will be carried out in Kericho, Kenya. 126 healthy adults will ben enrolled. Participants will be randomized into one of seven groups which have 15/3 vaccine/placebo recipients per group. Each participant will receive six injections (prim at week 0, 4, 12; boost at week 20, 32 and 56) and will be followed-up for a total of 108 weeks.
Interventions
BIOLOGICALEnv-C Plasmid DNA
2 mg per dose. Administered by intramuscular injection.
BIOLOGICALHIV Env gp145 C.6980 protein
100 µg per dose. Administered by intramuscular injection.
DRUGRehydragel®
Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
BIOLOGICALALF43
Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
BIOLOGICALdmLT
Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
DRUGPlacebo (IM)
0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
DRUGPlacebo (TCl)
Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
Sponsors
Walter Reed Army Institute of Research (WRAIR)
US Military HIV Research Program
The Emmes Company, LLC
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy, male and female participant aged 18 to 40 years and available for 26 months. * Must be at low risk for HIV infection per investigator assessment and using the study risk assessment tool. * Must be able to understand and complete the informed consent process. * Must be capable of reading English or Kiswahili. * Must agree to a home visit. * Must complete a Test of Understanding (TOU) before enrollment. Must answer 9 out of 10 questions correctly with a maximum of three attempts. * Must be in good general health without a clinically significant medical history. * HIV-uninfected per diagnostic algorithm within 45 days of enrollment. * Laboratory values: * Hemoglobin * 12.5-18.1 g/dL men * 11.0-16.1 g/dL women * White Cell Count * 2.7-7.7 x 10³ cells/µL men * 3.0-9.1 x 10³ cells/µL women * Platelets: * 125-370 10³ cells/µL men * 125-444 10³ cells/µL women * ALT and AST: ≤1.25 institutional upper limit of the reference range * Creatinine: ≤1.25 institutional upper limit of the reference range * Urinalysis: (dipstick) for blood and protein less than 1+ and negative glucose Female-Specific Criteria * Negative urine pregnancy test for women at screening, the day of each vaccination, and before any invasive procedure. * Already using and commits to continued use of an adequate birth control method for 45 days before to the first vaccination/placebo vaccination, and for at least 90 days after the final vaccine/placebo vaccination. Adequate birth control is defined as follows: Contraceptive medications delivered orally, intramuscularly, vaginally, or implanted, underneath the skin, surgical methods (hysterectomy or bilateral tubal ligation), condoms with spermicide, diaphragms, intrauterine device (IUD), vasectomy in a monogamous partner, or abstinence. Lymph Node Biopsy Inclusion Criteria * Body mass index (BMI) \<35 * Platelets \>150,000 * International normalized ration (INR) \<1.2 * Verbal report of no NSAIDS/aspirin for 7 days prior. * Negative pregnancy test for participants born female.
Exclusion criteria
A history of: * Three or more sexual partners in the previous 24 weeks. * Commercial sex work. * Non-adherence to condom use in the absence of a long-term monogamous relationship. * Intravenous drug use in the previous year. * A sexually transmitted infection in the previous 24 weeks. * Asplenia: any condition resulting in the absence of a functional spleen. * Bleeding disorder diagnosed by a medical doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions). * Breastfeeding or pregnant (positive pregnancy test) women or planning to become pregnant during the window between study enrollment and three months after the last vaccination visit. * Any past, ongoing, or in remission history of treated or untreated autoimmune disease. * Has known active Hepatitis B virus infection (or positive HBsAg). * Has known active Hepatitis C infection. * History of anaphylaxis or other serious adverse reaction to vaccines or allergies or reactions likely to be exacerbated by any component of the vaccine and placebo, including antibiotics or excipients. * Absolute Neutrophil Count (ANC) \<1.0 x 10³ cells/µL. * Participant has received any of the following substances: * Chronic use of therapies that may modify immune response, such as intravenous (IV) immune globulin and systemic corticosteroids (in doses of \>20 mg/day prednisone equivalent for periods exceeding 10 days). * The following exceptions are permitted and will not exclude study participation: * Use of corticosteroid nasal spray for rhinitis; * Topical corticosteroids for an acute uncomplicated dermatitis; or * A short course (10 days or less, or a single injection) of corticosteroid for a non-chronic condition (based on investigator clinical judgment) at least 2 weeks before enrollment. * Blood products within 120 days before HIV screening. * Immunoglobulins within 30 days before HIV screening. * Any experimental vaccine containing an adjuvant other than aluminum of an adjuvant not approved by the FDA or European Medicines Agency (EMA) as part of a licensed vaccine. * CERVARIX vaccine against HPV (containing AS04) * Receipt of any investigational HIV vaccine, investigational research agents or vaccine within 30 days before enrollment. * Anti-tuberculosis prophylaxis or therapy during the past 90 days before enrollment. * Any psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol compliance or impairs a participant's ability to give informed consent. * Major psychiatric illness and or substance abuse problems during the past 12 months that, in the opinion of the investigator, would preclude participation. * History of atopy or significant skin conditions. * Study site employees who are involved in the protocol and or may have direct access to the study-related area. Lymph Node Biopsy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of SAEs (Outcome 14) | Day 1-Day 728 | Incidence (number and percentage of participants) of SAEs by maximum severity and vaccination group |
| Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Day 1-Day 7 Post Vaccination 3 | Incidence (number and percentage of participants) of local reactogenicity events post dose 3 by symptom, maximum severity, and vaccination group. |
| Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Day 1-Day 7 Post Vaccination 4 | Incidence (number and percentage of participants) of local reactogenicity events post dose 4 by symptom, maximum severity, and vaccination group |
| Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Day 1-Day 7 Post Vaccination 5 | Incidence (number and percentage of participants) of local reactogenicity events post dose 5 by symptom, maximum severity, and priming dose group |
| Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Day 1-Day 7 Post Vaccination 6 | Incidence (number and percentage of participants) of local reactogenicity events post dose 6 by symptom, maximum severity, and vaccination group |
| Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Day 1-Day 7 Post Vaccination 1 | Incidence (number and percentage of participants) of systemic reactogenicity events post dose 1 by symptom, maximum severity, and priming dose group |
| Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Day 1-Day 7 Post Vaccination 2 | Incidence (number and percentage of participants) of systemic reactogenicity events post dose 2 by symptom, maximum severity, and priming dose group |
| Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Day 1-Day 7 Post Vaccination 3 | Incidence (number and percentage of participants) of systemic reactogenicity events post dose 3 by symptom, maximum severity, and vaccination group |
| Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Day 1-Day 7 Post Vaccination 4 | Incidence (number and percentage of participants) of systemic reactogenicity events post dose 4 by symptom, maximum severity, and vaccination group |
| Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Day 1-Day 7 Post Vaccination 5 | Incidence (number and percentage of participants) of systemic reactogenicity events post dose 5 by symptom, maximum severity, and priming dose group |
| Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Day 1-Day 7 Post Vaccination 6 | Incidence (number and percentage of participants) of systemic reactogenicity events post dose 6 by symptom, maximum severity, and vaccination group |
| Number of Related Unsolicited AEs (Outcome 13) | Day 1-Day 728 | Incidence (number and percentage of participants) of related unsolicited AEs by maximum severity and vaccination group. |
| Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Day 1-Day 7 Post Vaccination 1 | Incidence (number and percentage of participants) of local reactogenicity events post dose 1 by symptom, maximum severity, and priming dose group |
| Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Day 1-Day 7 Post Vaccination 2 | Incidence (number and percentage of participants) of local reactogenicity events post dose 2 by symptom, maximum severity, and priming dose group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Durability of Plasma IgG Binding Antibodies in Response to Differing DNA Priming Regimens | Thru Week 105 | Measured by binding antibody assays. |
| Area Under the Curve (AUC) for Plasma IgG Binding Antibodies in Response to Differing DNA Priming Regimens | Thru Week 105 | Measured by binding antibody assays. |
| Magnitude of Plasma IgG Binding Antibodies Between Groups With and Without Rehydragel® After HIV Env gp145 C.6980 Protein Boosting | Thru Week 105 | Measured by binding antibody assays. |
| Durability of Plasma IgG Binding Antibodies Between Groups With and Without Rehydragel® After HIV Env gp145 C.6980 Protein Boosting | Thru Week 105 | Measured by binding antibody assays. |
| AUC for Plasma IgG Binding Antibodies Between Groups With and Without Rehydragel® After HIV Env gp145 C.6980 Protein Boosting | Thru Week 105 | Measured by binding antibody assays. |
| Presence of Plasma IgG Binding Antibodies | Thru Week 105 | Functional antibodies assessed using rapid fluorometric Antibody-dependent Cell-Mediated Cytotoxicity (ADCC) Assay, Antibody-dependent Cell-mediated Phagocytosis (ADCP), Antibody-dependent Complement (ADC) activation assays, or other functional assays. Neutralizing antibodies assessed using cell line-based and PBMC assays with a panel of viruses from different HIV subtypes, including A, B, C, D, and other circulating recombinant forms (CRFs) such as AE and AG. |
| Presence of Plasma IgA Binding Antibodies | Thru Week 105 | Functional antibodies assessed using rapid fluorometric Antibody-dependent Cell-Mediated Cytotoxicity (ADCC) Assay, Antibody-dependent Cell-mediated Phagocytosis (ADCP), Antibody-dependent Complement (ADC) activation assays, or other functional assays. Neutralizing antibodies assessed using cell line-based and PBMC assays with a panel of viruses from different HIV subtypes, including A, B, C, D, and other circulating recombinant forms (CRFs) such as AE and AG. |
| Types of Cell-mediated Immune Responses | Thru Week 105 | Cryopreserved PBMC and lymph nodes will be stimulated with HIV-1-specific antigens and tested using standard (but not limited to) cellular immune assays which may include but are not limited to Intracellular cytokine Staining, ELISPOT, Lymphoproliferation assays, B-cell analysis, T-follicular helper cell and innate immune cell analysis. |
| Level of Cell-mediated Immune Responses | Thru Week 105 | Cryopreserved PBMC and lymph nodes will be stimulated with HIV-1-specific antigens and tested using standard (but not limited to) cellular immune assays which may include but are not limited to Intracellular cytokine Staining, ELISPOT, Lymphoproliferation assays, B-cell analysis, T-follicular helper cell and innate immune cell analysis. |
| Types of Mucosal Humoral Responses | Thru Week 104 | Including, but not limited to, plasma IgG and IgA binding antibodies to HIV Env proteins, IgG and IgA subclass, and functional assays. |
| Magnitude of Plasma IgG Binding Antibodies in Response to Differing DNA Priming Regimens | Thru Week 105 | Measured by binding antibody assays. |
Countries
Kenya
Participant flow
Pre-assignment details
See protocol for screening details.
Participants by arm
| Arm | Count |
|---|---|
| Group 1: Vaccine 3 doses of prime vaccination at weeks 0, 4, 12 followed by 3 doses of boost vaccination at weeks 20, 32, 56 | 17 |
| Group 2: Vaccine 3 doses of prime vaccination at weeks 0, 4, 12 followed by 3 doses of boost vaccination at weeks 20, 32, 56 | 16 |
| Group 3: Vaccine 3 doses of prime vaccination at weeks 0, 4, 12 followed by 3 doses of boost vaccination at weeks 20, 32, 56 | 17 |
| Group 4: Vaccine 3 doses of prime vaccination at weeks 0, 4, 12 followed by 3 doses of boost vaccination at weeks 20, 32, 56 | 16 |
| Group 5: Vaccine 3 doses of prime vaccination at weeks 0, 4, 12 followed by 3 doses of boost vaccination at weeks 20, 32, 56 | 16 |
| Group 6: Vaccine 3 doses of prime vaccination at weeks 0, 4, 12 followed by 3 doses of boost vaccination at weeks 20, 32, 56 | 18 |
| Group 7: Vaccine 3 doses of prime vaccination at weeks 0, 4, 12 followed by 3 doses of boost vaccination at weeks 20, 32, 56 | 17 |
| Pooled Placebo Pooled placebo arm. | 26 |
| Total | 143 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 2 | 1 | 0 | 0 | 1 | 3 | 1 | 1 |
| Overall Study | Non-adherence (protocol deviation) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Other: Declined | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Overall Study | Other: Moved from area | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Other: Vaccine not administered | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
| Overall Study | Participant withdrew consent | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| Overall Study | Withdrawn by Investigator | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Baseline characteristics
| Characteristic | Group 1: Vaccine | Group 2: Vaccine | Group 3: Vaccine | Group 4: Vaccine | Group 5: Vaccine | Group 6: Vaccine | Group 7: Vaccine | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous Age Years | 26.4 years STANDARD_DEVIATION 3.7 | 26.6 years STANDARD_DEVIATION 5.3 | 29.0 years STANDARD_DEVIATION 4.5 | 27.2 years STANDARD_DEVIATION 5.9 | 29.2 years STANDARD_DEVIATION 5 | 28.8 years STANDARD_DEVIATION 5.2 | 28.7 years STANDARD_DEVIATION 3.9 | 28.7 years STANDARD_DEVIATION 6 | 28.1 years STANDARD_DEVIATION 5 |
| Age, Customized 18-25 | 8 Participants | 8 Participants | 4 Participants | 8 Participants | 3 Participants | 5 Participants | 4 Participants | 9 Participants | 49 Participants |
| Age, Customized 26-30 | 6 Participants | 3 Participants | 6 Participants | 3 Participants | 8 Participants | 4 Participants | 9 Participants | 6 Participants | 45 Participants |
| Age, Customized 31-35 | 3 Participants | 4 Participants | 6 Participants | 2 Participants | 2 Participants | 8 Participants | 3 Participants | 8 Participants | 36 Participants |
| Age, Customized 36-40 | 0 Participants | 1 Participants | 1 Participants | 3 Participants | 3 Participants | 1 Participants | 1 Participants | 3 Participants | 13 Participants |
| BMI | 24.05 kg/m2 STANDARD_DEVIATION 5.13 | 22.49 kg/m2 STANDARD_DEVIATION 4.73 | 23.95 kg/m2 STANDARD_DEVIATION 3.84 | 21.87 kg/m2 STANDARD_DEVIATION 2.92 | 21.31 kg/m2 STANDARD_DEVIATION 3.3 | 22.00 kg/m2 STANDARD_DEVIATION 3.09 | 22.65 kg/m2 STANDARD_DEVIATION 3.76 | 24.37 kg/m2 STANDARD_DEVIATION 5.27 | 22.95 kg/m2 STANDARD_DEVIATION 4.23 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 17 Participants | 16 Participants | 17 Participants | 16 Participants | 16 Participants | 18 Participants | 17 Participants | 26 Participants | 143 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Level of Education Advanced degree | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Level of Education College/university | 5 Participants | 1 Participants | 3 Participants | 2 Participants | 3 Participants | 3 Participants | 2 Participants | 9 Participants | 28 Participants |
| Level of Education No formal education | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Level of Education Primary school completed | 5 Participants | 4 Participants | 4 Participants | 7 Participants | 7 Participants | 3 Participants | 5 Participants | 2 Participants | 37 Participants |
| Level of Education Primary school not completed | 2 Participants | 6 Participants | 6 Participants | 4 Participants | 2 Participants | 5 Participants | 7 Participants | 11 Participants | 43 Participants |
| Level of Education Secondary school completed | 3 Participants | 5 Participants | 0 Participants | 1 Participants | 1 Participants | 4 Participants | 3 Participants | 3 Participants | 20 Participants |
| Level of Education Secondary school not completed | 2 Participants | 0 Participants | 4 Participants | 2 Participants | 3 Participants | 2 Participants | 0 Participants | 1 Participants | 14 Participants |
| Marital Status Divorced / Separated | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Marital Status Married but living apart | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Marital Status Married or living as a couple | 11 Participants | 8 Participants | 12 Participants | 10 Participants | 10 Participants | 8 Participants | 10 Participants | 15 Participants | 84 Participants |
| Marital Status Single, never married | 6 Participants | 8 Participants | 4 Participants | 5 Participants | 5 Participants | 8 Participants | 6 Participants | 11 Participants | 53 Participants |
| Marital Status Widowed | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Primary Occupation Commerce/business | 4 Participants | 2 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 3 Participants | 4 Participants | 16 Participants |
| Primary Occupation Entertainment/Services/Hospitality | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Primary Occupation Farmer | 2 Participants | 5 Participants | 11 Participants | 6 Participants | 6 Participants | 7 Participants | 6 Participants | 10 Participants | 53 Participants |
| Primary Occupation Fisher/Fish trader | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Primary Occupation Housewife | 2 Participants | 1 Participants | 1 Participants | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 2 Participants | 10 Participants |
| Primary Occupation Military enlisted | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Primary Occupation Military officer | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Primary Occupation Other | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants | 2 Participants | 0 Participants | 6 Participants |
| Primary Occupation Personal or domestic services | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Primary Occupation Professional/managerial | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Primary Occupation Refuse to answer | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Primary Occupation Sex worker | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Primary Occupation Skilled trade (tailor, hairdresser, etc.) | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 4 Participants |
| Primary Occupation Student | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 3 Participants | 3 Participants | 0 Participants | 7 Participants | 21 Participants |
| Primary Occupation Truck driver | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Primary Occupation Unskilled laborer | 4 Participants | 5 Participants | 2 Participants | 4 Participants | 2 Participants | 5 Participants | 5 Participants | 2 Participants | 29 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 17 Participants | 16 Participants | 17 Participants | 16 Participants | 16 Participants | 18 Participants | 17 Participants | 26 Participants | 143 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 10 Participants | 8 Participants | 13 Participants | 9 Participants | 8 Participants | 11 Participants | 12 Participants | 15 Participants | 86 Participants |
| Sex: Female, Male Male | 7 Participants | 8 Participants | 4 Participants | 7 Participants | 8 Participants | 7 Participants | 5 Participants | 11 Participants | 57 Participants |
| Tribe Kalenjin | 12 Participants | 15 Participants | 16 Participants | 15 Participants | 11 Participants | 17 Participants | 15 Participants | 20 Participants | 121 Participants |
| Tribe Kikuyu | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Tribe Kisii | 3 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 6 Participants |
| Tribe Luhya | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 3 Participants | 6 Participants |
| Tribe Luo | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 6 Participants |
| Tribe Other | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants |
| Tribe Refuse to answer | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 17 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 17 | 0 / 16 | 0 / 23 |
| other Total, other adverse events | 15 / 17 | 15 / 16 | 14 / 16 | 13 / 16 | 13 / 16 | 13 / 17 | 13 / 16 | 17 / 23 |
| serious Total, serious adverse events | 1 / 17 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 17 | 0 / 16 | 0 / 23 |
Outcome results
Primary
Number of Related Unsolicited AEs (Outcome 13)
Incidence (number and percentage of participants) of related unsolicited AEs by maximum severity and vaccination group.
Time frame: Day 1-Day 728
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Related Unsolicited AEs (Outcome 13) | None | 32 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Related Unsolicited AEs (Outcome 13) | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Related Unsolicited AEs (Outcome 13) | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Related Unsolicited AEs (Outcome 13) | None | 32 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | None | 16 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | None | 16 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Group 7: | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Group 7: | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Group 7: | Number of Related Unsolicited AEs (Outcome 13) | None | 32 Participants |
| Group 7: | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Group 7: | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 1 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 1 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | None | 15 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | None | 17 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of Related Unsolicited AEs (Outcome 13) | None | 16 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Moderate / Grade 2 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | None | 23 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Severe / Grade 3 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Pooled Placebo | Number of Related Unsolicited AEs (Outcome 13) | Mild Grade 1 | 0 Participants |
Primary
Number of SAEs (Outcome 14)
Incidence (number and percentage of participants) of SAEs by maximum severity and vaccination group
Time frame: Day 1-Day 728
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of SAEs (Outcome 14) | None | 32 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of SAEs (Outcome 14) | Severe / Grade 3 | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of SAEs (Outcome 14) | Severe / Grade 3 | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of SAEs (Outcome 14) | None | 16 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of SAEs (Outcome 14) | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of SAEs (Outcome 14) | None | 32 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | None | 16 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | None | 16 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Group 7: | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Group 7: | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Group 7: | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Group 7: | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Group 7: | Number of SAEs (Outcome 14) | None | 33 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | None | 16 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | None | 17 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / dmLT / HIV Env gp145 C.6980 Protein (Group 7) | Number of SAEs (Outcome 14) | None | 16 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | None | 23 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Potentially Life-Threatening / Grade 4 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Moderate / Grade 2 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Severe / Grade 3 | 0 Participants |
| Pooled Placebo | Number of SAEs (Outcome 14) | Mild Grade 1 | 0 Participants |
Primary
Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1)
Incidence (number and percentage of participants) of local reactogenicity events post dose 1 by symptom, maximum severity, and priming dose group
Time frame: Day 1-Day 7 Post Vaccination 1
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | None | 33 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | None | 27 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | None | 32 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | None | 23 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | None | 33 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | None | 29 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | None | 28 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | None | 27 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | None | 30 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | None | 32 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | None | 31 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | None | 32 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | None | 30 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | None | 25 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | None | 32 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 8 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Mild (Grade 1) | 7 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | None | 26 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | None | 33 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | None | 33 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | None | 32 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | None | 10 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | None | 22 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | None | 23 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | None | 23 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | None | 23 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | None | 23 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | None | 105 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Mild (Grade 1) | 7 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Moderate (Grade 2) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | None | 107 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | None | 110 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 24 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 5 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Itching | Mild (Grade 1) | 8 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Any Solicited Local Reactogenicity Event | None | 85 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Mild (Grade 1) | 17 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | None | 111 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | None | 111 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Hardness | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
Primary
Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2)
Incidence (number and percentage of participants) of local reactogenicity events post dose 2 by symptom, maximum severity, and priming dose group
Time frame: Day 1-Day 7 Post Vaccination 2
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | None | 26 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | None | 27 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | None | 19 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | None | 19 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Mild (Grade 1) | 6 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | None | 25 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | None | 25 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 6 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | None | 28 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | None | 28 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | None | 28 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | None | 11 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | None | 11 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | None | 13 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | None | 18 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | None | 19 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | None | 19 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | None | 99 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 17 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Mild (Grade 1) | 16 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | None | 84 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Mild (Grade 1) | 8 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | None | 100 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | None | 98 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | None | 85 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Hardness | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Redness/Erythema | None | 100 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 2 by Priming Dose Group (Outcome 2) | Swelling/Induration | Mild (Grade 1) | 3 Participants |
Primary
Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3)
Incidence (number and percentage of participants) of local reactogenicity events post dose 3 by symptom, maximum severity, and vaccination group.
Time frame: Day 1-Day 7 Post Vaccination 3
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | None | 25 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | None | 25 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | None | 28 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | None | 26 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | None | 30 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | None | 30 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | None | 19 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | None | 19 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 10 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Mild (Grade 1) | 8 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | None | 88 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | None | 90 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | None | 97 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | None | 97 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | None | 98 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Itching | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Warmth | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 3 by Priming Dose Group (Outcome 3) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
Primary
Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4)
Incidence (number and percentage of participants) of local reactogenicity events post dose 4 by symptom, maximum severity, and vaccination group
Time frame: Day 1-Day 7 Post Vaccination 4
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 6 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 15 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 13 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 14 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 6 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 14 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 12 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 12 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 15 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 7 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 15 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 15 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 10 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 6 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 9 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 9 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 9 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 12 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 12 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 15 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 18 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 18 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 19 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Moderate (Grade 2) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | None | 79 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | Mild (Grade 1) | 22 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Pain/Tenderness | None | 80 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Warmth | None | 100 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Hardness | None | 104 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Itching | None | 100 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Redness/Erythema | None | 102 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 23 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 4 by Vaccination Group (Outcome 4) | Swelling/Induration | None | 101 Participants |
Primary
Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5)
Incidence (number and percentage of participants) of local reactogenicity events post dose 5 by symptom, maximum severity, and priming dose group
Time frame: Day 1-Day 7 Post Vaccination 5
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 10 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 10 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 12 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 12 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 14 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 11 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 11 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 13 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 12 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 12 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 21 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 21 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 21 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 21 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 21 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | None | 87 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 11 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Any Solicited Local Reactogenicity Event | None | 86 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Pain/Tenderness | Mild (Grade 1) | 10 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Hardness | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 5 by Vaccination Group (Outcome 5) | Itching | Moderate (Grade 2) | 0 Participants |
Primary
Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6)
Incidence (number and percentage of participants) of local reactogenicity events post dose 6 by symptom, maximum severity, and vaccination group
Time frame: Day 1-Day 7 Post Vaccination 6
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 10 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 9 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 11 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 11 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 14 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 15 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 14 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 20 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 20 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Mild (Grade 1) | 9 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | None | 97 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | None | 88 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | None | 94 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Warmth | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | None | 91 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Itching | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Swelling/Induration | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Any Solicited Local Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Hardness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Pain/Tenderness | Mild (Grade 1) | 6 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Local Events Post Vaccination 6 by Vaccination Group (Outcome 6) | Redness/Erythema | Mild (Grade 1) | 0 Participants |
Primary
Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7)
Incidence (number and percentage of participants) of systemic reactogenicity events post dose 1 by symptom, maximum severity, and priming dose group
Time frame: Day 1-Day 7 Post Vaccination 1
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Mild (Grade 1) | 13 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | None | 19 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | None | 31 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | None | 27 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | None | 17 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | None | 33 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | None | 32 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 14 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | None | 21 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Mild (Grade 1) | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | None | 31 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | None | 26 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | None | 31 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | None | 29 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | None | 21 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 10 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | None | 27 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | None | 32 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Mild (Grade 1) | 8 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | None | 27 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Mild (Grade 1) | 6 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | None | 27 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | None | 33 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Mild (Grade 1) | 7 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 17 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | None | 30 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | None | 32 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | None | 32 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | None | 32 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | None | 32 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Mild (Grade 1) | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | None | 26 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | None | 20 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | None | 11 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | None | 11 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | None | 8 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | None | 16 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 6 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | None | 12 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 11 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | None | 21 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | None | 23 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | None | 21 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | None | 17 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Mild (Grade 1) | 6 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | None | 12 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Mild (Grade 1) | 11 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Mild (Grade 1) | 10 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | None | 103 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Moderate (Grade 2) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Mild (Grade 1) | 6 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Mild (Grade 1) | 29 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | None | 84 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | None | 108 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 47 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | None | 113 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | None | 62 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | Mild (Grade 1) | 11 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Chills | None | 102 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Moderate (Grade 2) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | Mild (Grade 1) | 16 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Dizziness | None | 97 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fever | None | 108 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Fatigue/Tiredness | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | None | 73 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | Mild (Grade 1) | 11 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Arthralgia | None | 102 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 5 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Headache | Mild (Grade 1) | 39 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 1 by Priming Dose Group (Outcome 7) | Myalgia | Moderate (Grade 2) | 1 Participants |
Primary
Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8)
Incidence (number and percentage of participants) of systemic reactogenicity events post dose 2 by symptom, maximum severity, and priming dose group
Time frame: Day 1-Day 7 Post Vaccination 2
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | None | 22 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Mild (Grade 1)8 | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1)8 | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Mild (Grade 1)8 | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | None | 27 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | None | 22 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Mild (Grade 1)8 | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | None | 27 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Mild (Grade 1)8 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Mild (Grade 1)8 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | None | 21 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Moderate (Grade 2 | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Mild (Grade 1)8 | 4 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Mild (Grade 1)8 | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | None | 21 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Moderate (Grade 2 | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | None | 17 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1)8 | 6 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Mild (Grade 1)8 | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | None | 22 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Mild (Grade 1)8 | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | None | 22 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2 | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Mild (Grade 1)8 | 3 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Mild (Grade 1)8 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Mild (Grade 1)8 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | None | 30 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | None | 30 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Mild (Grade 1)8 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Mild (Grade 1)8 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | None | 28 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | None | 30 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | None | 25 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1)8 | 6 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | None | 31 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | None | 30 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1)8 | 6 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | None | 9 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Mild (Grade 1)8 | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Mild (Grade 1)8 | 3 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Moderate (Grade 2 | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Mild (Grade 1)8 | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | None | 19 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Mild (Grade 1)8 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Mild (Grade 1)8 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | None | 18 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Mild (Grade 1)8 | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Mild (Grade 1)8 | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Mild (Grade 1)8 | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Mild (Grade 1)8 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | None | 19 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1)8 | 5 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Mild (Grade 1)8 | 3 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | None | 17 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | None | 19 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | None | 17 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Mild (Grade 1)8 | 3 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Moderate (Grade 2 | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Mild (Grade 1)8 | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Mild (Grade 1)8 | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Moderate (Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Moderate (Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Moderate (Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Mild (Grade 1)8 | 5 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Mild (Grade 1)8 | 5 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | None | 92 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Mild (Grade 1)8 | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Mild (Grade 1)8 | 7 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2 | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Moderate (Grade 2 | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Moderate (Grade 2 | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | None | 94 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | None | 73 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Moderate (Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | None | 98 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Moderate (Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Mild (Grade 1)8 | 6 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Mild (Grade 1)8 | 7 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | None | 86 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | None | 94 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Mild (Grade 1)8 | 6 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1)8 | 26 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Moderate (Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | None | 94 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Myalgia | Moderate (Grade 2 | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 2 by Priming Dose Group (Outcome 8) | Fatigue/Tiredness | Mild (Grade 1)8 | 9 Participants |
Primary
Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9)
Incidence (number and percentage of participants) of systemic reactogenicity events post dose 3 by symptom, maximum severity, and vaccination group
Time frame: Day 1-Day 7 Post Vaccination 3
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | None | 26 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | None | 29 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 9 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | None | 30 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | None | 20 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | None | 28 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Mild (Grade 1) | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | None | 22 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | None | 21 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | None | 23 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | None | 22 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | None | 24 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | None | 30 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | None | 30 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | None | 28 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | None | 26 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | None | 29 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | None | 29 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | None | 18 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | None | 18 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | None | 19 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Moderate (Grade 2) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | None | 98 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | Mild (Grade 1) | 5 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fatigue/Tiredness | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | None | 84 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Mild (Grade 1) | 17 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Rash | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | Moderate (Grade 2) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Any Solicited Systemic Reactogenicity Event | None | 79 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Headache | Mild (Grade 1) | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 3 by Priming Dose Group (Outcome 9) | Arthralgia | Moderate (Grade 2) | 0 Participants |
Primary
Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10)
Incidence (number and percentage of participants) of systemic reactogenicity events post dose 4 by symptom, maximum severity, and vaccination group
Time frame: Day 1-Day 7 Post Vaccination 4
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 15 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 15 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 10 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 14 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 14 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 13 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 15 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 7 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 5 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 11 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 12 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 15 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 15 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 15 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 16 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 10 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 11 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 13 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 12 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 13 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 13 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 19 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 19 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 4 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 16 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 4 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 16 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | None | 102 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 79 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Mild (Grade 1) | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | None | 100 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | None | 102 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | None | 90 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 21 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Moderate (Grade 2) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | None | 101 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Headache | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | None | 99 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Mild (Grade 1) | 5 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Mild (Grade 1) | 5 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | None | 101 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Myalgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fever | None | 94 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Nausea | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Fatigue/Tiredness | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | None | 104 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 4 by Vaccination Group (Outcome 10) | Dizziness | Moderate (Grade 2) | 0 Participants |
Primary
Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11)
Incidence (number and percentage of participants) of systemic reactogenicity events post dose 5 by symptom, maximum severity, and priming dose group
Time frame: Day 1-Day 7 Post Vaccination 5
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 10 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 10 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 9 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 4 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 10 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 11 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 11 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 13 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 13 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 13 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 15 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 13 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 13 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 12 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 2 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 5 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 16 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 21 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 21 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 21 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 21 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 17 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 21 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 19 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 4 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | None | 91 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 13 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 82 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | Mild (Grade 1) | 6 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Dizziness | None | 91 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | None | 87 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fever | Moderate (Grade 2) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Nausea | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Fatigue/Tiredness | Mild (Grade 1) | 6 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Headache | Mild (Grade 1) | 9 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Arthralgia | None | 96 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | None | 97 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Rash | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 5 by Vaccination Group (Outcome 11) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
Primary
Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12)
Incidence (number and percentage of participants) of systemic reactogenicity events post dose 6 by symptom, maximum severity, and vaccination group
Time frame: Day 1-Day 7 Post Vaccination 6
Population: The safety population includes all participants who received at least one vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 10 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 11 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 8 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 12 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 1: Prime of Env-C Plasmid DNA Alone | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 13 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 14 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 12 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 2: Prime of Env-C Plasmid DNA / dmLT | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 10 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 9 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 11 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 3 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 10 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 11 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 12 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 9 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 10 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 3: Prime of Env-C Plasmid DNA / ALF43 | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 2 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 12 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 14 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 15 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Priming Dose Group 4: Prime of Env-C Plasmid DNA / ALF43 / HIV Env gp145 C.6980 Protein | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 4 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 11 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 13 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 15 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 1 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 1 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 14 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 13 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 14 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 1 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 13 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Group 7: | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 14 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 18 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 16 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 3 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 17 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 2 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 20 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 4 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| Pooled Placebo | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 20 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Chills | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | Mild (Grade 1) | 4 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Myalgia | None | 93 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | None | 97 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Mild (Grade 1) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | Mild (Grade 1) | 2 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Rash | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Mild (Grade 1) | 15 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | None | 94 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | None | 91 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Moderate (Grade 2) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | None | 94 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | None | 79 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Nausea | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fatigue/Tiredness | None | 95 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Mild (Grade 1) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Fever | Moderate (Grade 2) | 3 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Any Solicited Systemic Reactogenicity EventReactogenicity Event | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Mild (Grade 1) | 8 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Severe (Grade 3) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | None | 89 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Dizziness | Moderate (Grade 2) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Headache | Potentially Life-Threatening (Grade 4) | 0 Participants |
| All Participants Receiving Env-C Plasmid DNA | Number of Solicited Systemic Events Post Vaccination 6 by Vaccination Group (Outcome 12) | Arthralgia | Potentially Life-Threatening (Grade 4) | 0 Participants |
Secondary
Area Under the Curve (AUC) for Plasma IgG Binding Antibodies in Response to Differing DNA Priming Regimens
Measured by binding antibody assays.
Time frame: Thru Week 105
Secondary
AUC for Plasma IgG Binding Antibodies Between Groups With and Without Rehydragel® After HIV Env gp145 C.6980 Protein Boosting
Measured by binding antibody assays.
Time frame: Thru Week 105
Secondary
Durability of Plasma IgG Binding Antibodies Between Groups With and Without Rehydragel® After HIV Env gp145 C.6980 Protein Boosting
Measured by binding antibody assays.
Time frame: Thru Week 105
Secondary
Durability of Plasma IgG Binding Antibodies in Response to Differing DNA Priming Regimens
Measured by binding antibody assays.
Time frame: Thru Week 105
Secondary
Level of Cell-mediated Immune Responses
Cryopreserved PBMC and lymph nodes will be stimulated with HIV-1-specific antigens and tested using standard (but not limited to) cellular immune assays which may include but are not limited to Intracellular cytokine Staining, ELISPOT, Lymphoproliferation assays, B-cell analysis, T-follicular helper cell and innate immune cell analysis.
Time frame: Thru Week 105
Secondary
Magnitude of Plasma IgG Binding Antibodies Between Groups With and Without Rehydragel® After HIV Env gp145 C.6980 Protein Boosting
Measured by binding antibody assays.
Time frame: Thru Week 105
Secondary
Magnitude of Plasma IgG Binding Antibodies in Response to Differing DNA Priming Regimens
Measured by binding antibody assays.
Time frame: Thru Week 105
Secondary
Presence of Plasma IgA Binding Antibodies
Functional antibodies assessed using rapid fluorometric Antibody-dependent Cell-Mediated Cytotoxicity (ADCC) Assay, Antibody-dependent Cell-mediated Phagocytosis (ADCP), Antibody-dependent Complement (ADC) activation assays, or other functional assays. Neutralizing antibodies assessed using cell line-based and PBMC assays with a panel of viruses from different HIV subtypes, including A, B, C, D, and other circulating recombinant forms (CRFs) such as AE and AG.
Time frame: Thru Week 105
Secondary
Presence of Plasma IgG Binding Antibodies
Functional antibodies assessed using rapid fluorometric Antibody-dependent Cell-Mediated Cytotoxicity (ADCC) Assay, Antibody-dependent Cell-mediated Phagocytosis (ADCP), Antibody-dependent Complement (ADC) activation assays, or other functional assays. Neutralizing antibodies assessed using cell line-based and PBMC assays with a panel of viruses from different HIV subtypes, including A, B, C, D, and other circulating recombinant forms (CRFs) such as AE and AG.
Time frame: Thru Week 105
Secondary
Types of Cell-mediated Immune Responses
Cryopreserved PBMC and lymph nodes will be stimulated with HIV-1-specific antigens and tested using standard (but not limited to) cellular immune assays which may include but are not limited to Intracellular cytokine Staining, ELISPOT, Lymphoproliferation assays, B-cell analysis, T-follicular helper cell and innate immune cell analysis.
Time frame: Thru Week 105
Secondary
Types of Mucosal Humoral Responses
Including, but not limited to, plasma IgG and IgA binding antibodies to HIV Env proteins, IgG and IgA subclass, and functional assays.
Time frame: Thru Week 104